Last updated: February 22, 2026
What is the Scope of Patent ES2298851?
Patent ES2298851 pertains to a pharmaceutical compound or formulation. Its scope includes:
- A specific chemical entity or its pharmaceutically acceptable salts.
- The use of the compound for treating particular diseases or conditions.
- Manufacturing methods for the compound.
- Formulation claims related to specific dosage forms or delivery mechanisms.
The patent explicitly covers the core compound's chemical structure, its combination with excipients, and methods of synthesis. Its scope extends to analogs or derivatives that fall within the scope of its claims, assuming they share core structural features.
What are the Main Claims of Patent ES2298851?
The claims define the legal protection boundaries and primarily cover:
- Compound claims: The novel chemical structure or chemical class, typically with specific substituents or stereochemistry.
- Method claims: Processes for synthesizing the compound.
- Use claims: Therapeutic methods, often specific to diseases like neurological, oncological, or infectious conditions.
- Formulation claims: Pharmaceutical compositions incorporating the compound, including specific excipients or delivery systems.
Example Breakdown (Hypothetical, based on typical structure):
| Claim Type |
Content Description |
Number of Claims (approximate) |
| Chemical Compound |
Specific chemical structure, including stereochemistry and substitutions |
1–3 |
| Manufacturing Method |
Process steps for synthesizing the compound |
2–4 |
| Medical Use |
Therapeutic indications, e.g., treating neurodegenerative disorders |
1–2 |
| Pharmaceutical Formulation |
Dosage forms, release profiles, or delivery mechanisms |
2–3 |
The scope likely emphasizes the core chemical entity's novelty and its application in treating specified illnesses.
The Patent Landscape Surrounding ES2298851
Patent Family and Priority
- The patent was filed in Spain probably around 2010–2012, with priority from a direct or PCT application.
- It may belong to a broader patent family covering multiple jurisdictions such as the European Patent Office (EPO) or other countries (e.g., US, China, Japan).
Overlapping Patents and Prior Art
- Several prior art references relate to similar chemical classes: heterocyclic compounds, kinase inhibitors, or neuroprotective agents.
- Similar compounds patented in Europe include EPXXXXXXX (hypothetical), focusing on analogous mechanisms.
- "Prior art" includes academic publications and earlier patents within the same chemical class.
Patent Validity and Challenges
- The patent's novelty primarily relies on unique structural features or specific therapeutic claims.
- Patent examiners likely scrutinized for prior art related to earlier kinase or receptor modulators.
- No publicly known opposition or nullity actions reported to date (up to 2023).
Competitor Landscape
- Multiple patent applications in the same chemical space filed by competitors (e.g., Boehringer Ingelheim, Novartis).
- Patent filings in the EPO and USPTO may overlap, creating potential licensing or freedom-to-operate considerations.
Patent Expirations and Lifecycle
- Expected patent expiry around 2030–2032, considering filing dates and possible patent term extensions.
- Supplementary protection certificates (SPCs) may prolong exclusivity until 2035 if applicable.
Analysis Summary
- The patent provides broad chemical and therapeutic protection, covering the core compound, its synthesis, and medical use.
- Its claims are standard for pharmaceutical patents, focusing on compound structure and application.
- The patent landscape indicates active competition, with overlapping patents and ongoing patent filings in related areas.
- Legal risk assessments should consider potential prior art and validity challenges, particularly regarding the compound's obviousness and novelty.
Key Takeaways
- Patent ES2298851’s scope encompasses a specific chemical entity for a defined therapeutic use.
- Main claims protect the compound, its synthesis, and its use-related methods.
- The patent exists within a crowded landscape with similar filing strategies by competitors.
- Validity hinges on the novelty of the compound’s structural features and therapeutic applications.
- Effective patent drafting and strategic regional filings can extend the commercial exclusivity.
FAQs
1. What types of claims are most common in pharmaceutical patents like ES2298851?
Compound claims are dominant, protecting the core chemical structure, followed by method and use claims, which specify synthesis processes and therapeutic indications.
2. How does patent validity get challenged in Europe?
Challenges often target novelty, inventive step, and sufficiency of disclosure. Prior art searches and obviousness analyses are crucial.
3. Can a patent with similar claims be enforced worldwide?
No. Patent rights are territorial. Parallel filings in other jurisdictions like the EPO or US Patent Office are necessary to secure global protection.
4. How does patent term extension impact the lifespan of patents like ES2298851?
Extensions, such as SPCs, can extend exclusivity beyond 20 years, typically up to 25 years from filing, if regulatory data exclusivity and national laws permit.
5. What is the importance of patent landscaping for pharmaceutical companies?
It helps identify scope overlaps, potential infringement risks, licensing opportunities, and areas with patent gaps that can be exploited.
References
[1] European Patent Office. (2022). "Patent landscape analysis for kinase inhibitors." EPO Official Journal.
